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1173-89 He/icobecferPy/ori Eradication Improves Prognosis of 
Coronary Artery Disease Through a Mechanism Not 
Related With Platelet Activation 
Alessandro Sionis, lgnasi Elizalde, Magda Heras, Nuria Casanovas, Salvador D&z-A& 
Teresa Mark&l, Miguel Lozano, Sonia Perez, Julian Gonzalez, Gines Saw, Josep M. 
Pique, Hospital Clinic, Barcelona, Spain 
Background: Epidemiological association between Helimbacter pylori (HP) infection 
and coronaty artery disease (CAD) has been suggested. but underlying pathophysiologi- 
cal links remain unknown. Platelet activation and aggregation have been reported in ani- 
mal models. This pilot randomized controlled trial evaluates the impad of HP infection 
and eradication on platelet activation and inflammatory markers in patients (pts) with 
CAD as well as the influence of HP status on subsequent adverse coronary events (car- 
diac death, angina or myocardial infarction). 
Methods: Ninety survivors after an acute coronary event not requiring surgical revascu- 
larization were included. HP status was assessed with an urea breath test and fibrino- 
gen, platelet surface expression of CD62P. CD63 and CD41/61 (flow cytometry), soluble 
P selectin (ELISA), high-sensitivity C reactive protein, and C.pneumoniaeserology were 
measured at baseline and at two-months follow-up. HP positive pts were randomized to 
receive a 7-day course of omeprazole. amoxycillin and metronidszole or corresponding 
placebos (randomization ratio 3:2). Pis were followed-up for one year or until death or 
readmission with an acute coronary syndrome. 
Results: No baseline differences were observed between HP positive (n = 49) and HP 
negative (n = 41) pts. Among HP positive pts. 18 received placebo and 31 active medica- 
tion with HP eradication in 21 cases. No differences were observed neither in inflamma- 
tory or platelet activation markers nor in anti-Chlamydial serology between pts with 
persistent or resolved HP infection. However at 6 and 12 months, a recurrent coronary 
event was observed in 35% and 55% of pts with persisting HP infection vs 10% and 25% 
of pts in whom HP was either absent or eradicated respectively (log-rank = 0.01, Breslow 
= 0.01). Only final HP status (RR 2.7 [95% Cl 1.2-6.31; p=O.O14) and dyslipemia (RR 3.0 
[95% Cl 1.0-9.01; ~~0.046) were selected as independent predictors of recurrent coro- 
nary events. Conclusions HP infection does not induce significant platelet activation in 
pts with CAD. HP infected pts have an increased probability to suffer a recurrent coro- 
nary event which may be reverted by eradicating the infection. 
1173-90 Baseline Creatinine Clearance Provides Additional 
Prognostic Information to TIMI Risk Score in Non-ST 
Elevation Acute Coronary Syndromes 
Carlos T. Aauiar, Jorge Ferreira, Pedro A. Goncalves, Marisa Trabulo, Ricardo Seabra- 
Games, Santa Cruz Hospital, Carnaxide, Portugal 
Background: The TIMI risk score is a simple tool that is established for risk stratification 
and therapeutic decision making in patients (pts) with non-ST-elevation acute coronary 
syndromes (NSTE-ACS). We investigated whether baseline renal function provides prog- 
nostic information in addition to this score. 
Methods: We studied 433 pts admitted due to NSTE-ACS. Creatinine clearance (CrCl) 
was determined using the Cockroft-Gault equation (using baseline Cr level). Study end- 
point was death or nonfatal myocardial infarction (Ml) by 30 days follow-up. ROC curve 
analysis was used to determine the best discriminatory value for CrCI. Additionally, sur- 
vival status at 1 year follow-up was determined for all pts. 
Results: TIMI risk score was >3 in 257 (59.4%) pts, and CrCl was ~55 mlimin in 126 
(29.1%). In multivariable analyses, both TIMI risk score >3 (OR 4.7; 95% Cl, 1.4-16.2) 
and CrCl ~55 mllmin (OR 3.6; 95% Cl, 1.5-6.2) independently predicted 30.day progno- 
sis. Similarly, both TIMI risk score >3 (OR 4.0; 95% Cl. 1.1-13.7) and CrCl ~55 ml/min 
(OR 4.2; 95% Cl, 1.7-10.3) were independent predictors of l-year mortality. The com- 
bined use of TIMI risk score and baseline CrCl identified pts at low, intermediate and high 
risk for both the 30-day endpoint and 1 -year mortality (see table). 
Conclusions: In pts with NSTE-ACS. baseline renal function provides short and long 
term prognostic information, additional to the TIMI risk score. The combined use of these 
risk indicators may help guide more cost-effective treatment. 
Endpoint 
Death/MI: 30 days 
Death: 1 year 
TIMI 5 3 and 
CrCl,55 
(n=136) 
1.5% 
1.5% 
TlMlz 3or 
CrCIc 55 
(n=211) 
4.3% 
3.3% 
TIMID Band 
CrCIe 55 
(n=66) 
16.3% 
15.1% 
1173-91 Elevated Titre of Antihuman Heat Shock Protein 60 
Predicts an Adverse Medium-Term Prognosis in 
Patients With Unstable Angina 
David H. Birnie, Lewis E. Vickers, Stewart Hillis, John Norrie, Stuart M. Cobbe, Glasgow 
University, Glasgow, United Kingdom 
Background There is evidence that the inflammatory state of coronary atherosclerosis is 
important in determining plaque stability. Increased CRP levels have prognostic implica- 
tions and interest has turned lo other aspects of inflammation including anbbodies to heat 
shock proteins expressed within plaques. Their prognostic importance in coronary dis- 
ease has not been addressed. Methods Consecutive emergency admissions with acute 
chest pain of suspected cardiac origin but without ST elevation or significant CK-MB ele- 
vation were eligible for inclusion. After discharge, they were followed-up by review of 
their hospital case records and directly by telephone and letter. The clinical endpoints 
were CHD death, non-fatal MI, CABG, PTCA, angiogram and readmission with further 
cardiac ischaemic chest pain. Anti-human heat shock protein 60 (anti-huhsp 60) and 
anti-mycabacterial heat shock protein 65 (anti-myhsp65) titles were assayed on samples 
drawn on the morning after admission. ResultsA total of 566 patients were enrolled from 
a single centre. During follow-up (mean of 304 days, range 1 to 768 days), 277 patients 
had an endpoint. Table 1 details hazard ratios for anti-huhspP60 and anti-myhsp65 in 
quartiles for the combined endpoint conditional on age, smoking, log(CRP), hypertension 
and diabetes in a multivariate Cox model. Conclusions Patients admitted with acute car- 
diac chest pain and elevated levels of anti-huhsp 60 had an adverse medium term prog- 
nosis. Anti-myhsp65 titres were not predictive. 
Table I Hazard ratios for anti-hubspP60 and anti-myhsp65 in quartiles for the combined 
endpoint 
Anti-huhsp 60 titre Hazard P Value Anti-myhsp 65 titre Hazard P Value 
(Au/ml) Ratio (AU/ml) Ratio 
<16 1 .o <9 1 .o 
16to ~24 1.65 0.005 9to<17 1.02 0.69 
24 to <36 1.41 0.066 17 to <31 0.75 0.12 
>36 1.55 0.016 z-31 0.94 0.75 
OVERA OVERA 
LL LL 
P=O.O3 PzO.33 
1173-114 Outcomes Based on Time to Angiography in Patients 
With Non-ST Elevation Acute Coronary Syndromes 
Khaled A. Daiani, Sanjaya Khanal, Mouaz Al-Mallah, lyengar Hirshikesh, Noel Gutierrez, 
and Michael P. Hudson, Henry Ford Heart and Vascular Institute. Detroit. Ml 
Background: Recent clinical trials and guidelines suppori invasive risk stratification with 
early coronaty angiography and revascularization for patients with Non-ST-elevation 
acute coronary syndromes (ACS). The optimal timing of angiography from hospital 
admission however is unceltain:therefore.we retrospectivelv investiaated whether tlmina _ 
of angiography affects outcomes in patients with Non-ST-elevation ACS. 
Methods: Studv oooulation consisted of 636 oatients admitted to the coronaw care unit ,. 
between 1997- 2000 with Non-ST-elevation ACS who underwent angiography during the 
same hospital stay. Patients were categorized into three groups based on the time inter- 
val between admission and angiography: ~24 hours, 24.46hours and >46hours. Six- 
month incidence of death and/or myocardial infarction was determined and compared 
between groups. 
Results: Table below summarizes baseline characteristics and B-month outcomes 
according to angiography group. Following multivariate adjustment, anglography group 
remained signifantly associated with survival with angiography delays >46hours associ- 
ated with worse survival. 
Conclusions: Younger age. male gander, absence of prior ML were associated with 
increased likelihood of angiography within 46 hours of hospital admission. Delay of 
angiography >46 hours was associated with worse survival while angiography delay 24. 
46 hours yielded optimal survival results. 
Baseline Charactenstics and Outcomes 
Variable 
Age (s.d.) 
Female (%) 
Prior Ml (%) 
Index PCI (%) 
MI,(%) 
Death or MI, (%) 
Death, (%) 
Q4hrs 24-46hrs >46hrs 
(N=314) (N=267) (N=255) 
62.4 (12.4) 62.6 (13) 65.1 (11.6) 
37.3 39 50.6 
25.6 25.1 36.4 
56.7 47.20 41.6 
4.5 6.7 7.6 
10.2 11.2 16.5 
7.4 5.6 12.3 
D-ValUe 
0.02 
0.003 
< 0.001 
0.001 
0.22 
0.067 
0.03 
